newsfilter
← Latest News
GlobeNewswire·

SkinHealth Systems Reports Second Quarter 2026 Financial Results

SKIN
  • SkinHealth Systems Inc. reported Q2 2026 net sales of $72.1 million, a 7.8% decrease from $78.2 million in Q2 2025, driven by lower delivery systems & consumables sales.
  • The company sold 770 delivery systems in Q2 2026, down from 957 units sold in the prior year period.
  • Gross margin improved to 68.4% in Q2 2026 from 62.8% in Q2 2025, while adjusted gross margin rose to 71.8% from 65.9%.
  • Operating expenses decreased to $45.8 million in Q2 2026 from $51.8 million in Q2 2025, primarily due to lower personnel-related costs.
  • The company reported a net loss of $2.7 million for Q2 2026, compared to net income of $19.7 million in Q2 2025, largely due to an $18.1 million net gain on note exchanges in the prior year.
  • Adjusted EBITDA for Q2 2026 was $17.0 million, an increase from $13.9 million in Q2 2025, resulting from lower operational spend & higher gross margins.
  • Revised 2026 financial guidance projects full-year net sales between $280 million & $290 million, with adjusted EBITDA guidance set between $39 million & $46 million.
  • Regional sales data shows declines across Americas, APAC, & EMEA for both delivery systems & consumables during the first half of 2026.
  • The company transitioned sales in Australia, New Zealand, & China to distributor partners during the second quarter, discontinuing direct sales in those markets.
  • Cash & cash equivalents stood at $206.1 million as of June 30, 2026, a decrease from $232.7 million at the end of 2025.
  • The company's 1.25% Convertible Senior Notes are scheduled to mature in October 2026, with current debt obligations listed at $345.2 million combined for current & non-current portions.
  • SkinHealth Systems maintains strategic priorities focused on strengthening the Hydrafacial franchise, increasing installed base productivity, & expanding its portfolio with complementary technologies.